CORONA Remedies Limited has informed the Exchange regarding 'Communication to Shareholders - Intimation on Tax Deduction on Dividend'.
CORONA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Corona Remedies has notified shareholders about a recommended final dividend of ₹10 per equity share (100% on face value of ₹10) for FY 2025-26. The dividend is subject to approval at the 22nd Annual General Meeting, with the record date set for June 19, 2026. Under the Income Tax Act 2025 (effective April 2026), the company is required to deduct TDS on dividend payments at varying rates based on shareholder category—resident individuals with valid PAN submitting Form 121 can claim nil TDS, while non-residents face 20% withholding plus surcharge/cess or beneficial treaty rates. Key deadlines include updating PAN, KYC details, and bank particulars with depository participants, and submitting tax exemption documents to the RTA (Bigshare Services) by June 19, 2026. Incomplete documentation will result in higher withholding tax rates.
Shareholders should submit required tax documents by June 19, 2026 to avoid higher TDS deductions. Failure to link PAN with Aadhaar will result in 20% withholding. The dividend payment is contingent on AGM approval.